The National
Petrochemical Company, or NPC, and the Syndicate of Manufacturers of
Pharmaceutical, Chemical and Pharmaceutical Packaging Materials signed a
memorandum of understanding to identify investment opportunities and develop
joint projects across the petrochemical-to-pharmaceutical value chain.
The agreement was signed
by Mohammad Mottaghi, NPC’s director of downstream industries development, and
Faramarz Ekhtaraei, chairman of the syndicate’s board, at the closing ceremony
of the eighth International Pharmex exhibition.
Under the agreement, the
two sides will assess petrochemical production capabilities against the
pharmaceutical industry’s raw-material requirements and identify opportunities
to convert basic and intermediate petrochemical products into specialty chemicals,
intermediates and active pharmaceutical ingredients, or APIs.
Identifying Gaps in
the Supply Chain
Mottaghi said the
immediate priority is to map the pharmaceutical sector’s requirements and
compare them with products and capabilities available within the petrochemical
industry.
Some parts of the supply
chain still lack domestic production capacity, creating opportunities for new
investment, he said. Identifying those gaps could allow specific projects to be
developed and presented to companies and investors with the technical and
financial capacity to implement them.
The initiative is
intended to go beyond simply replacing imports. Projects will be assessed based
on their technical and economic feasibility, required technologies and their
ability to strengthen links between the two industries.
One of the key areas
under consideration is the production of pharmaceutical intermediates. These
materials form an important link between petrochemical feedstocks and finished
pharmaceutical products, and expanding domestic production could create an additional
layer of value within the country's chemical industry.
Petrochemical products
entering the pharmaceutical supply chain must also meet requirements that
differ from conventional industrial standards. Some materials require
additional purification and processing before they can be used as
pharmaceutical raw materials.
Mottaghi said these
requirements need to be incorporated into the development of the new supply
chain from the outset.
From an Agreement to
Projects
The memorandum calls for
the preparation of a petrochemical-to-pharmaceutical value-chain map,
identification of pharmaceutical raw materials and required technologies,
assessment of applicable standards and development of a portfolio of strategic
projects.
The process is expected
to begin with a detailed assessment and prioritization of pharmaceutical
industry requirements. Those needs will then be matched with petrochemical
products and production capabilities to identify missing links.
The next stage will be to
develop specific projects with technical and economic justifications and
present them to qualified investors and companies for implementation.
A joint steering
committee and secretariat are also envisaged under the agreement to monitor
progress and ensure that the initiative moves beyond planning.
Mottaghi said the
significance of the memorandum will ultimately depend on whether it produces
actual investment and manufacturing projects. Even completing a limited number
of economically viable links between petrochemicals and pharmaceuticals would
give the agreement an impact well beyond the signing itself.
Medical Materials Also
in Focus
The proposed cooperation
extends beyond pharmaceutical ingredients to polymer products used in medical
equipment, supplies and packaging.
Iran's petrochemical
industry already produces a broad range of basic and intermediate materials
that could potentially serve as inputs for downstream medical applications.
Developing these links could create additional domestic demand for
petrochemical products while supporting local production of higher-value
materials.
The initiative therefore
has implications for both industries: pharmaceutical manufacturers could gain
access to a broader domestic source of raw materials, while petrochemical
producers could expand their product portfolios and capture more value further
downstream.
Building a Domestic
Supply Base
Ekhtaraei said the
agreement could provide a framework for using petrochemical capabilities to
supply basic materials required by pharmaceutical manufacturers and for
developing joint investment projects between the two sectors.
The approach reflects a
broader effort to strengthen domestic industrial chains by connecting existing
production capacity with industries that require specialized chemical inputs.
For Iran's petrochemical
sector, the potential payoff lies in moving beyond the sale of basic
commodities toward specialty chemicals and other products with greater value
added. For the pharmaceutical industry, a more developed domestic chemical
supply chain could strengthen access to strategic raw materials and
intermediates.
The effectiveness of the
initiative will depend on how quickly the two sides can identify commercially
viable gaps, secure the required technologies and attract investment. The
memorandum provides the framework; turning it into operating plants and reliable
supply chains will determine its economic impact.